{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-283212","form_type":"8-K","ticker":"BCAB","cik":"0001826892","company_name":"BioAtla, Inc.","filed_at":"2024-12-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.869116+00:00","generated_at":"2026-05-29T00:28:54.605316+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"BioAtla raises $9.2M in registered direct offering to fund mid-stage TCE and ADC programs","bullets":["Sold 9,679,158 shares and accompanying warrants at $0.9520/unit; gross proceeds ~$9.2M.","Warrants exercisable at $1.19/share for 5.5 years, beginning 6 months after issuance.","Proceeds to fund BA3182 Phase 1 dose escalation data (2Q25) and Phase 2 expansion data (1H26).","Proceeds also to fund mecbotamab vedotin Phase 2B data in mKRAS NSCLC (1H26).","Officers and directors subject to 75-day lock-up; company restricted on equity issuance for 75 days."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-283212","json":"https://secwatch.observer/filing/0001193125-24-283212.json","markdown":"https://secwatch.observer/filing/0001193125-24-283212.md","text":"https://secwatch.observer/filing/0001193125-24-283212.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826892/000119312524283212/0001193125-24-283212-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826892/000119312524283212/d823541d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T00:28:54.605316+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}